A possible mechanism linking hyperglycemia and reduced high-density lipoprotein cholesterol levels in diabetes

Abstract

This study investigated the role of glucose in the biogenesis of high-density lipoprotein cholesterol (HDL-C). Mouse primary peritoneal macrophages were harvested and maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing glucose of various concentrations. The cells were divided into 3 groups in terms of different glucose concentrations in the cultures: Control group (5.6 mmol/L glucose), high glucose concentration groups (16.7 mmol/L and 30 mmol/L glucose). ATP-binding cassette transporter A1 (ABCA1) mRNA expression in the macrophages was detected by semi-quantitative RT-PCR 24, 48 and 72 h after glucose treatment. The results showed that ABCA1 mRNA expression in the 16.7 mmol/L glucose group was not significantly different from that in the control group at all testing time points (P>0.05 for each). In the 30 mmol/L glucose group, macrophage ABCA1 mRNA expression was not changed significantly at 24 h (P=0.14), but was substantially decreased by 40.4% at 48 h (P=0.009) and by 48.1% at 72 h (P=0.015) as compared with that in the control group. It was concluded that ABCA1 is of vital importance for HDL-C biogenesis. High glucose may hamper HDL-C biogenesis by decreasing ABCA1 expression, which contributes to low HDL-C level in diabetes.

Keywords

reverse cholesterol transport / diabetes / high-density lipoprotein cholesterol / ATP-binding cassette transporter A1

References

[1] MazzoneT., ChaitA., PlutzkyJ.. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet, 2008, 371(9626): 1800-1809

[2] BarterP., GottoA.M., LaRosaJ.C., et al.. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med, 2007, 357(13): 1301-1310

[3] GordonT., CastelliW.P., HjortlandM.C., et al.. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med, 1977, 62(5): 707-714

[4] SinghI.M., ShishehborM.H., AnsellB.J.. High-density lipoprotein as a therapeutic target: a systematic review. JAMA, 2007, 298(7): 786-798

[5] BeckmanJ.A., CreagerM.A., LibbyP.. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA, 2002, 287(19): 2570-2581

[6] Brooks-WilsonA., MarcilM., CleeS.M., et al.. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet, 1999, 22(4): 336-345

[7] TallA.R., WangN.. Tangier disease as a test of the reverse cholesterol transport hypothesis. J Clin Invest, 2000, 106(10): 1205-1207

[8] Baldán, BojanicD.D., EdwardsP.A.. The ABCs of sterol transport. J Lipid Res, 2009, 50(Suppl): S80-S85

[9] van EckM., BosI.S., KaminskiW.E., et al.. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc Natl Acad Sci USA, 2002, 99(9): 6298-6303

[10] MilicevicZ., RazI., BeattieS.D., et al.. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care, 2008, 31(Suppl2): S155-S160

[11] SemenkovichC.F.. Insulin resistance and atherosclerosis. J Clin Invest, 2006, 116(7): 1813-1822

[12] Soro-PaavonenA., WatsonA.M., LiJ., et al.. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes, 2008, 57(9): 2461-2469

[13] HarjaE., BuD.X., HudsonB.I., et al.. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest, 2008, 118(1): 183-194

[14] GleissnerC.A., SandersJ.M., NadlerJ., et al.. Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis. Arterioscler Thromb Vasc Biol, 2008, 28(6): 1137-1143

[15] VerrierE., WangL., WadhamC., et al.. PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase. Circ Res, 2004, 94(11): 1515-1522

[16] KoyamaH., NishizawaY.. Platelet in progression of atherosclerosis: a potential target in diabetic patients. Curr Diabetes Rev, 2005, 1(2): 159-165

[17] VaidyulaV.R., BodenG., RaoA.K.. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets, 2006, 17(8): 577-585

[18] KrupinskiJ., TuruM.M., FontM.A., et al.. Increased tissue factor, MMP-8, and D-dimer expression in diabetic patients with unstable advanced carotid atherosclerosis. Vasc Health Risk Manag, 2007, 3(4): 405-412

[19] MontecuccoF., SteffensS., MachF.. Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. Mediators Inflamm, 2008, 2008: 767623

[20] de SouzaL.F., JardimF.R., SauterI.P., et al.. High glucose increases RAW 264.7 macrophages activation by lipoteichoic acid from Staphylococcus aureus. Clin Chim Acta, 2008, 398(1–2): 130-133

[21] OramJ.F.. Tangier disease and ABCA1. Biochim Biophys Acta, 2000, 1529(1–3): 321-330

[22] BodziochM., OrsóE., KluckenJ., et al.. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet, 1999, 22(4): 347-351

[23] Frikke-SchmidtR., NordestgaardB.G., JensenG.B., et al.. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest, 2004, 114(9): 1343-1353

[24] OramJ.F., HeineckeJ.W.. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev, 2005, 85(4): 1343-1372